GUTS

Fractyl Health, Inc.

Price Chart

Latest Quote

$0.80

-0.02 (-2.67%)

Current Price

Previous Close	$0.83
Open	$0.83
Day High	$0.84
Day Low	$0.78
Volume	417,413

Fetched: 2026-06-24T16:05:18

Stock Information

Shares Outstanding	158.65M
Total Debt	$60.82M
Cash Equivalents	$63.17M
Net Income	$-108.00M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$127.70M
EPS (TTM)	$-1.31
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$128.85M
Income	$-108.00M
Book/sh	$0.14
Cash/sh	$0.40
Employees	100

Financial Ratios

Quick Ratio	4.10
Current Ratio	4.28
Debt/Eq	284.50

Returns & Margins

ROA	-63.64%
ROE	-778.33%

Ownership

Insider Ownership	1.35%
Institutional Ownership	52.47%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-1.48
P/B	5.96

Analyst Data

Recommendation	none
Target Price	$5.24

Technical Indicators

SMA20	$0.79
SMA50	$0.75
SMA200	$1.09
RSI	54.24
ATR	0.0752

Shares Float	143.27M
Short Float	1.63%
Short Ratio	1.02
Volatility	2.34
Rel Volume	0.23

Performance History

Week	+3.72%
Month	-11.55%
Quarter	+87.19%
6 Months	-63.41%
YTD	-64.23%
Year	-50.01%
10 Years	-93.74%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-24	$0.80	417,413
2026-06-23	$0.83	593,900
2026-06-22	$0.87	1,792,700
2026-06-18	$0.86	1,410,500
2026-06-17	$0.85	2,402,000
2026-06-16	$0.78	6,907,500
2026-06-15	$0.85	1,736,200
2026-06-12	$0.85	3,080,900
2026-06-11	$0.72	697,300
2026-06-10	$0.73	1,127,100
2026-06-09	$0.66	1,211,700
2026-06-08	$0.67	862,900
2026-06-05	$0.68	2,941,900
2026-06-04	$0.73	2,168,600
2026-06-03	$0.76	1,285,800
2026-06-02	$0.79	1,555,400
2026-06-01	$0.87	1,380,600
2026-05-29	$0.81	1,595,700
2026-05-28	$0.84	1,454,300
2026-05-27	$0.86	1,052,200
2026-05-26	$0.92	1,706,100

About Fractyl Health, Inc.

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. The company also develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

📰 Latest News

Fractyl Health Inc (GUTS) Cleared for RJVA-001 Trial. Let’s Look At Funding

Insider Monkey • 2026-06-12T03:23:59Z

Fractyl Health (GUTS) Is Up 14.0% After First GLP-1 Gene Therapy Trial Win And Profit Turnaround

Simply Wall St. • 2026-05-16T20:13:33Z

A Look At Fractyl Health (GUTS) Valuation After New Gene Therapy Trial Approval And First Quarter Net Income

Simply Wall St. • 2026-05-14T13:19:04Z

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga • 2026-05-13T17:06:16Z

Fractyl Health Inc (GUTS) Q1 2026 Earnings Call Highlights: Pivotal Trial Progress and ...

GuruFocus.com • 2026-05-13T05:02:00Z

Fractyl Health Q1 Earnings Call Highlights

MarketBeat • 2026-05-13T00:25:01Z

Inhibrx delivers ‘differentiated’ cancer drug data; Fractyl starts diabetes gene therapy trial

BioPharma Dive • 2026-05-11T10:00:00Z

Fractyl Health, Inc. Common Stock Q4 2025 Earnings Call Summary

Moby • 2026-03-25T12:30:00Z

Fractyl Health Inc (GUTS) Q4 2025 Earnings Call Highlights: Navigating Financial Challenges ...

GuruFocus.com • 2026-03-25T03:01:48Z

Fractyl Health Q4 Earnings Call Highlights

MarketBeat • 2026-03-24T21:41:10Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$0	$50,000	$77,000	$0
Cost Of Revenue	$0	$50,000	$77,000	$0
Total Revenue	$0	$93,000	$120,000	$0
Operating Revenue	$0	$93,000	$120,000	$0
Expenses
Total Expenses	$96,816,000	$93,624,000	$50,956,000	$49,385,000
Other Income Expense	$-45,678,000	$20,691,000	$-27,515,000	$2,135,000
Other Non Operating Income Expenses	$-4,777,000	$2,783,000	$-20,721,000	$2,311,000
Net Non Operating Interest Income Expense	$1,540,000	$4,146,000	$1,260,000	$797,000
Operating Expense	$96,816,000	$93,574,000	$50,879,000	$49,385,000
Total Other Finance Cost	-	-	-	$-797,000
General And Administrative Expense	-	-	-	$15,031,000
Interest Expense	-	-	-	-
Interest Expense Non Operating	-	-	-	-
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-140,954,000	$-68,694,000	$-77,091,000	$-46,453,000
Net Interest Income	$1,540,000	$4,146,000	$1,260,000	$797,000
Interest Income	$1,540,000	$4,146,000	$1,260,000	$797,000
Normalized Income	$-100,053,000	$-86,602,000	$-70,297,000	$-46,277,000
Net Income From Continuing And Discontinued Operation	$-140,954,000	$-68,694,000	$-77,091,000	$-46,453,000
Total Operating Income As Reported	$-96,816,000	$-93,531,000	$-50,836,000	$-49,385,000
Net Income Common Stockholders	$-140,954,000	$-70,431,000	$-94,271,000	$-63,633,000
Net Income	$-140,954,000	$-68,694,000	$-77,091,000	$-46,453,000
Net Income Including Noncontrolling Interests	$-140,954,000	$-68,694,000	$-77,091,000	$-46,453,000
Net Income Continuous Operations	$-140,954,000	$-68,694,000	$-77,091,000	$-46,453,000
Pretax Income	$-140,954,000	$-68,694,000	$-77,091,000	$-46,453,000
Interest Income Non Operating	$1,540,000	$4,146,000	$1,260,000	$797,000
Operating Income	$-96,816,000	$-93,531,000	$-50,836,000	$-49,385,000
Gross Profit	$0	$43,000	$43,000	$0
Special Income Charges	-	-	$0	$-313,000
Per Share
Diluted EPS	$-0.92	$-1.62	$-1.98	$-1.34
Basic EPS	$-0.92	$-1.62	$-1.98	$-1.34
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-54,786,000	$-110,762,000	$-43,756,000	$-48,757,000
Total Unusual Items	$-40,901,000	$17,908,000	$-6,794,000	$-176,000
Total Unusual Items Excluding Goodwill	$-40,901,000	$17,908,000	$-6,794,000	$-176,000
Reconciled Depreciation	$1,129,000	$677,000	$286,000	$452,000
EBITDA (Bullshit earnings)	$-95,687,000	$-92,854,000	$-50,550,000	$-48,933,000
EBIT	$-96,816,000	$-93,531,000	$-50,836,000	$-49,385,000
Diluted Average Shares	$153,372,044	$43,541,527	$47,607,201	$82,428,363
Basic Average Shares	$153,372,044	$43,541,527	$47,607,201	$47,607,201
Diluted NI Availto Com Stockholders	$-140,954,000	$-70,431,000	$-94,271,000	$-63,633,000
Gain On Sale Of Security	$-40,901,000	$17,908,000	$-6,794,000	$137,000
Research And Development	$74,536,000	$70,471,000	$38,038,000	$34,354,000
Selling General And Administration	$22,280,000	$23,103,000	$12,841,000	$15,031,000
Preferred Stock Dividends	-	$1,737,000	$17,180,000	$17,180,000
Other Special Charges	-	-	-	$313,000
Other Gand A	-	-	-	$15,031,000

Fetched: 2026-06-18

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$9,458,000	$28,424,000	$-325,062,000	$-252,319,000
Total Assets	$121,402,000	$108,077,000	$76,212,000	$60,956,000
Total Non Current Assets	$33,826,000	$36,314,000	$40,564,000	$9,327,000
Other Non Current Assets	$4,592,000	$4,921,000	$9,792,000	$7,680,000
Current Assets	$87,576,000	$71,763,000	$35,648,000	$51,629,000
Other Current Assets	$6,036,000	$4,226,000	$2,029,000	$2,360,000
Inventory	$0	$73,000	$73,000	$0
Cash Cash Equivalents And Short Term Investments	$81,540,000	$67,464,000	$33,209,000	$49,269,000
Cash And Cash Equivalents	$81,540,000	$67,464,000	$33,209,000	$49,269,000
Restricted Cash	-	$0	$315,000	$0
Receivables	-	$0	$22,000	$0
Accounts Receivable	-	$0	$22,000	$0
Debt
Total Debt	$61,646,000	$62,500,000	$86,391,000	$19,475,000
Long Term Debt And Capital Lease Obligation	$56,542,000	$57,544,000	$83,660,000	$18,225,000
Long Term Debt	$30,586,000	$30,162,000	$55,152,000	$17,760,000
Current Debt And Capital Lease Obligation	$5,104,000	$4,956,000	$2,731,000	$1,250,000
Net Debt	-	-	$21,943,000	-
Current Debt	-	-	-	-
Other Current Borrowings	-	-	-	-
Liabilities
Total Liabilities Net Minority Interest	$111,944,000	$79,653,000	$401,274,000	$313,275,000
Total Non Current Liabilities Net Minority Interest	$93,615,000	$59,878,000	$390,086,000	$305,964,000
Other Non Current Liabilities	$663,000	$998,000	-	$2,000
Derivative Product Liabilities	$36,410,000	$1,336,000	$19,096,000	$407,000
Current Liabilities	$18,329,000	$19,775,000	$11,188,000	$7,311,000
Other Current Liabilities	$961,000	$831,000	$575,000	$36,000
Payables And Accrued Expenses	$12,264,000	$13,988,000	$7,882,000	$6,025,000
Payables	$1,574,000	$3,240,000	$553,000	$980,000
Accounts Payable	$1,574,000	$3,240,000	$553,000	$980,000
Non Current Deferred Liabilities	-	-	-	-
Current Deferred Liabilities	-	-	-	-
Equity
Common Stock Equity	$9,458,000	$28,424,000	$-325,062,000	$-252,319,000
Total Equity Gross Minority Interest	$9,458,000	$28,424,000	$-325,062,000	$-252,319,000
Stockholders Equity	$9,458,000	$28,424,000	$-325,062,000	$-252,319,000
Retained Earnings	$-556,264,000	$-415,310,000	$-346,616,000	$-269,525,000
Preferred Securities Outside Stock Equity	-	$0	$287,330,000	$287,330,000
Other
Ordinary Shares Number	$153,372,044	$48,755,451	$47,896,908	$47,552,616
Share Issued	$153,372,044	$48,755,451	$47,896,908	$47,552,616
Tangible Book Value	$9,458,000	$28,424,000	$-325,062,000	$-252,319,000
Invested Capital	$40,044,000	$58,586,000	$-269,910,000	$-234,559,000
Working Capital	$69,247,000	$51,988,000	$24,460,000	$44,318,000
Capital Lease Obligations	$31,060,000	$32,338,000	$31,239,000	$1,715,000
Total Capitalization	$40,044,000	$58,586,000	$-269,910,000	$-234,559,000
Additional Paid In Capital	$565,721,000	$443,734,000	$21,554,000	$17,206,000
Capital Stock	$1,000	$0	$0	$0
Common Stock	$1,000	$0	$0	$0
Preferred Stock	$0	$0	$0	-
Long Term Capital Lease Obligation	$25,956,000	$27,382,000	$28,508,000	$465,000
Current Capital Lease Obligation	$5,104,000	$4,956,000	$2,731,000	$1,250,000
Current Accrued Expenses	$10,690,000	$10,748,000	$7,329,000	$5,045,000
Net PPE	$29,234,000	$31,393,000	$30,772,000	$1,647,000
Accumulated Depreciation	$-2,724,000	$-1,595,000	$-4,831,000	$-4,545,000
Gross PPE	$31,958,000	$32,988,000	$35,603,000	$6,192,000
Leases	$599,000	$599,000	$3,766,000	$3,466,000
Construction In Progress	$94,000	$94,000	$77,000	$40,000
Other Properties	$29,509,000	$30,539,000	$30,907,000	$1,842,000
Machinery Furniture Equipment	$1,756,000	$1,756,000	$853,000	$844,000
Properties	$0	$0	$0	$0

Fetched: 2026-06-18

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-90,885,000	$-67,286,000	$-43,182,000	$-46,299,000
Operating Activities
Operating Cash Flow	$-90,328,000	$-65,521,000	$-42,823,000	$-46,243,000
Cash Flow From Continuing Operating Activities	$-90,328,000	$-65,521,000	$-42,823,000	$-46,243,000
Operating Gains Losses	$40,901,000	$-17,908,000	$6,794,000	$177,000
Investing Activities
Capital Expenditure	$-557,000	$-1,765,000	$-359,000	$-56,000
Investing Cash Flow	$-557,000	$-1,765,000	$-359,000	$-56,000
Cash Flow From Continuing Investing Activities	$-557,000	$-1,765,000	$-359,000	$-56,000
Financing Activities
Issuance Of Capital Stock	$85,401,000	$103,695,000	$0	$0
Financing Cash Flow	$104,961,000	$101,226,000	$27,437,000	$4,350,000
Cash Flow From Continuing Financing Activities	$104,961,000	$101,226,000	$27,437,000	$4,350,000
Net Common Stock Issuance	$85,401,000	$103,695,000	$0	-
Common Stock Issuance	$85,401,000	$103,695,000	$0	-
Net Other Financing Charges	-	$-2,854,000	$-963,000	-
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Other
Repayment Of Debt	$-457,000	$-187,000	$-84,000	$-16,046,000
Interest Paid Supplemental Data	$4,300,000	$3,127,000	$762,000	$7,000
End Cash Position	$85,795,000	$71,719,000	$37,779,000	$53,524,000
Beginning Cash Position	$71,719,000	$37,779,000	$53,524,000	$95,473,000
Changes In Cash	$14,076,000	$33,940,000	$-15,745,000	$-41,949,000
Proceeds From Stock Option Exercised	$20,017,000	$572,000	$52,000	$321,000
Net Issuance Payments Of Debt	$-457,000	$-187,000	$28,348,000	$4,029,000
Net Long Term Debt Issuance	$-457,000	$-187,000	$28,348,000	$4,029,000
Long Term Debt Payments	$-457,000	$-187,000	$-84,000	$-16,046,000
Net PPE Purchase And Sale	$-557,000	$-1,765,000	$-359,000	$-56,000
Purchase Of PPE	$-557,000	$-1,765,000	$-359,000	$-56,000
Change In Working Capital	$-395,000	$9,592,000	$989,000	$-1,242,000
Change In Other Working Capital	$-186,000	$2,329,000	$74,000	$1,122,000
Change In Other Current Liabilities	$-1,278,000	$1,098,000	$563,000	-
Change In Payables And Accrued Expense	$-1,252,000	$8,340,000	$116,000	$-919,000
Change In Accrued Expense	$414,000	$5,654,000	$543,000	$-929,000
Change In Payable	$-1,666,000	$2,686,000	$-427,000	$10,000
Change In Account Payable	$-1,666,000	$2,686,000	$-427,000	$10,000
Change In Prepaid Assets	$2,248,000	$-2,197,000	$331,000	$-1,445,000
Change In Inventory	$73,000	$0	$-73,000	$0
Change In Receivables	$0	$22,000	$-22,000	$0
Changes In Account Receivables	$0	$22,000	$-22,000	$0
Other Non Cash Items	$2,307,000	$-3,614,000	$21,903,000	$-2,315,000
Stock Based Compensation	$6,684,000	$14,426,000	$4,296,000	$3,138,000
Depreciation Amortization Depletion	$1,129,000	$677,000	$286,000	$452,000
Depreciation And Amortization	$1,129,000	$677,000	$286,000	$452,000
Depreciation	$1,129,000	$677,000	$286,000	$452,000
Gain Loss On Investment Securities	$40,901,000	$-17,908,000	$6,794,000	$-137,000
Net Income From Continuing Operations	$-140,954,000	$-68,694,000	$-77,091,000	$-46,453,000
Issuance Of Debt	-	$0	$28,432,000	$20,075,000
Long Term Debt Issuance	-	$0	$28,432,000	$20,075,000
Gain Loss On Sale Of PPE	-	-	$0	$1,000
Net Short Term Debt Issuance	-	-	-	$-16,037,000
Short Term Debt Payments	-	-	-	$-16,037,000

Fetched: 2026-06-18